Larimar Therapeutics, Inc.

DB:ZA71 Stock Report

Market Cap: €377.4m

Larimar Therapeutics Valuation

Is ZA71 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZA71 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZA71's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZA71's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZA71?

Key metric: As ZA71 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ZA71. This is calculated by dividing ZA71's market cap by their current book value.
What is ZA71's PB Ratio?
PB Ratio2x
BookUS$198.40m
Market CapUS$393.05m

Price to Book Ratio vs Peers

How does ZA71's PB Ratio compare to its peers?

The above table shows the PB ratio for ZA71 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
FYB Formycon
1.4x31.5%€827.2m
HPHA Heidelberg Pharma
2.9x-33.0%€103.9m
BIO3 Biotest
2x29.3%€1.4b
2INV 2invest
1xn/a€63.8m
ZA71 Larimar Therapeutics
2x6.7%€393.0m

Price-To-Book vs Peers: ZA71 is expensive based on its Price-To-Book Ratio (2x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does ZA71's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
ZA71 2.0xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ZA71 is good value based on its Price-To-Book Ratio (2x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is ZA71's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZA71 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ZA71's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZA71 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.75
€20.07
+249.0%
33.4%€34.34€11.79n/a11
Nov ’25€7.20
€19.07
+164.8%
35.8%€33.10€8.38n/a11
Oct ’25€5.70
€18.62
+226.7%
39.9%€32.68€8.28n/a8
Sep ’25€7.10
€20.64
+190.7%
38.8%€33.24€8.42n/a6
Aug ’25€7.60
€20.64
+171.6%
38.8%€33.24€8.42n/a6
Jul ’25€6.55
€20.64
+215.1%
38.8%€33.24€8.42n/a6
Jun ’25€6.40
€20.64
+222.5%
38.8%€33.24€8.42n/a6
May ’25€6.10
€18.34
+200.6%
40.5%€24.92€6.64n/a6
Apr ’25€6.60
€17.24
+161.2%
44.8%€24.71€6.58n/a5
Mar ’25€10.50
€15.16
+44.4%
46.0%€23.35€6.71n/a5
Feb ’25€5.30
€10.64
+100.8%
39.3%€15.68€4.15n/a5
Jan ’25€4.08
€10.85
+165.8%
37.7%€15.74€4.17n/a5
Dec ’24€3.08
€10.74
+248.6%
37.7%€15.59€4.13n/a5
Nov ’24€2.72
€10.87
+299.6%
37.7%€15.78€4.18€7.205
Oct ’24€4.04
€10.87
+169.1%
37.7%€15.78€4.18€5.705
Sep ’24€3.52
€10.74
+205.1%
37.7%€15.59€4.13€7.105
Aug ’24€3.84
€10.64
+177.1%
37.3%€15.38€4.07€7.605
Jul ’24€2.84
€10.55
+271.4%
34.9%€13.93€4.18€6.555
Jun ’24€3.42
€10.55
+208.4%
34.9%€13.93€4.18€6.405
May ’24€4.08
€10.60
+159.8%
26.2%€13.93€6.50€6.105
Apr ’24€3.72
€10.60
+185.0%
26.2%€13.93€6.50€6.605
Mar ’24€6.10
€9.92
+62.6%
36.6%€14.98€3.74€10.505
Feb ’24€4.44
€9.92
+123.3%
36.6%€14.98€3.74€5.305
Jan ’24€3.72
€9.92
+166.6%
36.6%€14.98€3.74€4.085
Dec ’23€2.96
€11.82
+299.3%
18.6%€15.45€9.65€3.084
Nov ’23€3.12
€12.42
+298.0%
19.4%€16.38€10.24€2.724

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

5.1%

1Y

22.9%